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 Abstract  
Abnormal glycosylation is a typical hallmark of the transition from healthy to neoplastic 
tissues. Although the importance of glycans and glycan-binding proteins in cancer-related 
processes such as tumor cell adhesion, migration, metastasis and immune escape has been 
largely appreciated, our awareness of the impact of lectin-glycan recognition in tumor 
vascularization is relatively new. Regulated glycosylation can influence vascular biology by 
controlling trafficking, endocytosis and signaling of endothelial cell (EC) receptors including 
vascular endothelial growth factor receptors (VEGFRs), platelet endothelial cell adhesion 
molecule (PECAM), Notch and integrins. In addition, glycans may control angiogenesis by 
regulating migration of endothelial tip cells and influencing EC survival and vascular 
permeability. Recent evidence indicated that changes in the EC surface glycome may also 
serve ‘on-and-off’ switches that control galectin binding to signaling receptors by displaying 
or masking specific glycan epitopes. These glycosylation-depedent lectin-receptor 
interactions can link tumor hypoxia to EC signaling and control tumor sensitivity to anti-
angiogenic treatment. 
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Glycobiology of the tumor microenvironment 
Glycosylation, the dynamic process responsible for creating the complex cellular portfolio of 
glycan structures, involves the synchronized action of glycosyltransferases and glycosidases 
(Ohtsubo and Marth, 2006). This process is dynamically regulated during cellular activation 
and differentiation and changes dramatically in response to cellular stress and environmental 
signals (Rabinovich and Croci, 2012). At the cellular level, different glycan structures can 
selectively regulate trafficking, localization and turnover of glycoprotein receptors (Boscher et 
al., 2011) and play essential roles in cellular recognition, adhesion, communication and 
signaling (Ohtsubo and Marth, 2006). Deciphering the information encoded by the cellular 
glycome has proven to be challenging because of the non-template nature of carbohydrate 
synthesis and the macro- and micro-heterogeneity of glycosylation patterns (Mariño et al., 
2010). However, it is now clear that endogenous glycan-binding proteins or lectins can 
decode and translate glycan-containing information into functional cellular responses (van 
Kooyk and Rabinovich, 2008). 
 Abnormal glycosylation has been largely appreciated as a hallmark of the transition 
from healthy to neoplastic tissue (Varki et al., 2009). In fact, glycans and glycan-binding 
proteins contribute to tumor progression by influencing homotypic and heterotypic cellular 
interactions, promoting tumor cell migration and metastasis and fostering immune escape 
strategies. Moreover, it has become increasingly evident that glycans also play important 
roles in tumor angiogenesis. Here we will review recent data on the role of lectin-glycan 
recognitions sytems in endothelial cell (EC) signaling and tumor vascularization and will 
discuss their contribution to angiogenic rescue programs developed in response to anti-
angiogenic therapy. 
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Glycans in vascular signaling programs: regulation and function  
Blood vessels deliver oxygen and nutrients, remove waste and represent the central highway 
through which immune cells migrate (Potente et al., 2011). Vessels are comprised of a 
monolayer of ECs that are covered by vascular smooth muscle cells (also called pericytes) 
that establish direct cell-cell interactions and offer mechanical and functional support (Kerbel, 
2008). In response to environmental cues, ECs are capable of displaying a variety of 
metabolic and immunological functions (Potente et al., 2011). In adult healthy organs, 
vessels are quiescent and rarely form new branches. However, under pathological conditions 
such as cancer, ischemia, inflammation and infectious diseases, ECs restart growing 
programs and respond to angiogenic signals to form new blood vessels from existing ones; a 
process termed angiogenesis (Carmeliet and Jain, 2011). However, in spite of the formation 
of a highly dense vascular network, tumor-associated vessels are often abnormal, leaky and 
immature, leading to aggravation of tumor hypoxia, promotion of tumor metastasis and 
resistance to treatments. Abnormal angiogenesis, thus represents an important tumor 
Achilles' heel and an advantage for the development of novel anti-tumor treatments 
(Carmeliet and Jain, 2011).  
Analysis of gene expression profiles revealed distinct sets of genes that are up- or 
down-regulated in healthy versus tumor-associated vessels. Of 170 transcripts predominantly 
expressed in the endothelium, 46 were specifically elevated in the endothelium associated to 
malignant colorectal tissues compared to normal blood vessels (St. Croix et al., 2000). 
Moreover, another study identified 17 genes (including vimentin, CD59, HMGB1 and IGFBP7) 
that were specifically overexpressed in tumor-associated vessels as compared to angiogenic 
endothelium of normal tissues (van Veijnum et al., 2006). Interestingly, glycan-related genes 
including glycosyltransferases and glycosidases can also be up- or down-regulated during the 
angiogenesis process (Garcia-Vallejo et al., 2006; Willhauck-Fleckenstein et al., 2010). 
Garcia-Vallejo and colleagues identified a set of glycosyltransferases, mannosidases and 
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 sulfotransferases that are differentially expressed in activated versus resting human ECs 
(Garcia-Vallejo et al., 2006). 
Remarkably, the EC glycome is highly sensitive to environmental signals, including 
cytokines and growth factors (Croci et al., 2014). In response to immunosuppressive (IL-10 
or TGF-β1) or pro-angiogenic (fibroblast growth factor-2; FGF2) cytokines, human ECs 
showed increased branching of 1,6 N-glycan structures and elongation of poly-LacNAc 
terminals, while displayed reduced expression of α2,6-linked sialic acid. These glycosylation 
changes facilitated binding of the endogenous lectin galectin-1 (Gal-1) to ECs and favored 
activation of pro-angiogenic signaling pathways (Croci et al., 2014). In contrast, ECs exposed 
to pro-inflammatory cytokines (IFN-γ, IL-17) showed reduced 1,6-N-glycan branching and 
increased α2,6-sialylation which prevented Gal-1 binding and angiogenesis. However, not 
only cytokines and growth factors altered the EC glycophenotype as hypoxia (a hallmark 
feature of the tumor microenvironment) induced pronounced up-regulation of neutral N-
glycans and diminished expression of tri- and tetra-sialylated N-glycans on ECs, which 
enhanced Gal-1 binding, EC signaling and angiogenesis (Croci et al., 2014). Thus, hypoxic, 
immunosuppressive or pro-inflammatory stimuli may serve as ‘on-and-off’ switches that 
selectively unmask or mask Gal-1-specific glyco-epitopes and controls EC signaling and 
angiogenesis. This particular ‘glycan switch’ (characterized by low expression of 2,6 sialic 
acid) is not restricted to ECs, as it is also a hallmark of immunological processes such as 
differentiation of T helper (Th)1 and Th17 cells (Toscano et al., 2007), dendritic cell 
maturation (Bax et al., 2007) and conversion of microglial cells toward an M1 phenotype 
(Starossom et al., 2012). Whether a distinctive glycosylation signature could delineate the 
vasculature of tumor-associated versus inflammatory microenvironments or could serve to 
distinguish vessels at different stages of tumor progression still remains to be explored. 
Although less appreciated, compared to the well-established roles of glycans in the 
control of innate and adaptive immunity (Rabinovich and Croci, 2012), compeling evidence 
indicates that glycosylation is integral to different angiogenesis-related processes. An 
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 example illustrating this concept is the dual regulation of angiogenesis by Notch receptor 
signaling depending on its glycosylation profile. Notch can be modulated by various 
posttranslational modifications of the receptors, such as the addition of fucose residues by 
protein O-fucosyltransferase 1 (POFUT1) to the extracellular epidermal growth factor (EGF)-
like repeats, which can be further modified by the Fringe family of -1,3-N-acetyl-
glucosaminyltransferases. Fringe enhances the activation of Notch in response to Delta-like 
ligands, but has the opposite effect for Serrate/Jagged ligands (Stanley and Guidos, 2009). It 
has been demonstrated that, in cells expressing the Fringe glycosyltransferase, Jagged1 acts 
a potent proangiogenic regulator that antagonizes Dll4-Notch signaling and controls EC tip 
formation (Benedito et al., 2009). Thus, Notch glycosylation may serve to differentially 
control vascularization programs and sprouting angiogenesis. Interestingly, another example 
highlighting the influence of glycosylation in angioregulatory circuits was provided by 
Kitazume and colleagues (2010) who demonstrated a central role for 2,6-linked sialic acid 
in modulating homophilic interactions of PECAM and controlling EC survival and 
angiogenesis. Additionally, Xu et al. (2011) showed a pivotal role for heparan sulfate 
proteoglycans in limiting vascular endothelial growth factor (VEGF)-induced vascular 
hyperpermeability. In this regard, interruption of heparan sulfate biosynthesis using a 
peracetylated 4-deoxy analogue of the heparan sulfate constituent GlcNAc, which was 
activated intracellularly into UDP-4-deoxy-GlcNAc, attenuated angiogenic signaling and 
prevented neovessel formation (van Wijk et al., 2013). Thus, regulated glycosylation can 
control different events in the angiogenesis cascade including ligand-binding activity, 
receptor trafficking and signaling, EC tip formation, sprouting and vascular permeability.  
 
Lectin-glycan recognition systems in vascular biology 
As mentioned above, subtle variations in the cellular glycophenotype could alter 
vascular processes by displaying or masking ligands for endogenous lectins, which translate 
glycan-containing information into functional responses (Garner and Baum, 2008). Currently, 
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 imited information is available regarding the contribution of C-type lectins or siglecs to the 
control of angiogenesis, with the exception of CLEC-14a, a C-type lectin involved in EC 
migration and filopodia formation (Ki et al., 2013). In contrast, an increasing number of 
studies support the central role of galectins, a family of -galactoside-binding lectins, in the 
control of vascular signaling programs (Thijssen et al., 2013). Galectins (Gal-1, -3, -8 and -9) 
can differentially control angiogenesis programs by engaging a different set of EC surface 
receptors, activating distinct signaling pathways and/or regulating different events in the 
angiogenic cascade (Thijssen et al., 2013). In this regard, Gal-1 binds to neuropilin-1 (NRP-
1) or to VEGFR2 where it modulates receptor segregation, internalization and trafficking 
through glycosylation-dependent mechanisms, leading to VEGFR2 phosphorylation and 
signaling via the Raf/extracellular signal-regulated kinase (ERK) and Akt (Hsieh et al, 2008; 
Thijssen et al., 2010; Croci et al., 2012; Mathieu et al., 2012; D’Haenne et al., 2013, Croci et 
al., 2014). More recently, Wu and colleagues showed that, in addition to its role in the 
regulation of EC proliferation, migration and morphogenesis, Gal-1 also plays a role in the 
control of vascular permeability through activation of NRP-1, VEGFR1 and Akt signaling (Wu 
et al., 2014).  
On the other hand, Gal-3 controls EC biology through binding to N-glycans on v3 
integrin and modulating cell surface retention of VEGFR2 (Nangia-Makker et al., 2000; 
Markowska et al., 2010; Markowska et al., 2011), whereas Gal-8 triggers EC signaling 
through binding to the activated leukocyte cell adhesion molecule (ALCAM; CD166) 
(Cardenas-Delgado et al., 2011). Interestingly, recent evidence indicated a dose- and 
context-dependent effect of the Gal-9∆5, a splice variant isoform of Gal-9, on EC 
proliferation, migration and morphogenesis (Heusschen et al., 2014). Moreover, induction of 
platelet-derived angiogenic molecules (including VEGF-A and endostatin) has been 
documented as an alternative regulatory pathway by which galectins can control 
angiogenesis (Etulain et al., 2014). As different galectins may be up- or down-regulated in 
different tumor microenvironments (Langbein et al., 2007; Laderach et al., 2013; Dalotto-
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 Moreno et al., 2013) a detailed ‘galectin signature’ of different tumor types will disclose the 
best targets for anti-angiogenic therapy.   
Recent evidence showed that specific interactions between Gal-1 and complex N-
glycans may serve to link tumor hypoxia to vascularization programs in models of Kaposi’s 
sarcoma, melanoma, lung adenocarcinoma and T-cell lymphoma (Croci et al., 2012; 2014). 
Remarkably, hypoxia favored a Gal-1-specific glycophenotype in ECs, as it increased the 
amounts of 1-6GlcNAc-branched N-glycans and poly-LacNAc structures and reduced 2,6 
sialylation. Furthermore, exposure to hypoxic conditions up-regulated Gal-1 expression in 
different tumor types through HIF-1-dependent (Le et al., 2005; Zhao et al., 2011) or 
ROS/NF-B-dependent (Croci et al., 2012) mechanisms.  
Targeting Gal-1 expression eliminated vascularization and suppressed growth in 
several tumor types including melanoma (Thijssen et al., 2006; 2010; Mathieu et al., 2012; 
Croci et al., 2014), Kaposi’s sarcoma (Croci et al., 2012), prostate carcinoma (Laderach et 
al., 2013), lung adenocarcinoma (Croci et al., 2014), T-cell lymphoma (Croci et al., 2014), 
pancreatic adenocarcinoma (Martinez-Bosch et al., 2014) and glioblastoma (Verschuere et 
al., 2014). Furthermore, interfering with Gal-1-induced angiogenesis has demonstrated 
clinical benefits not only in cancer settings but also in pregnancy-associated pathologies 
including pre-eclampsia (Freitag et al., 2013) and endometriosis (Baston et al., 2014), thus 
emphasizing the key role of Gal-1 as a general target of anti-angiogenic therapies. Analysis 
of human tumor biopsies revealed that Gal-1 expression correlated with the number of blood 
vessels in prostate adenocarcinoma (Laderach et al., 2013), non-small cell lung 
adenocarcinoma (NSCLC) (Carlini et al., 2014) and Kaposi’s sarcoma (Croci et al., 2012). 
Interestingly, Gal-1-induced angiogenesis appeared to be independent of canonical pro-
angiogenic factors including VEGF, FGF2, oncostatin M, angiopoietin-like 4 (ANGPTL-4) and 
platelet-derived growth factor (PDGF)- (Croci et al., 2012; 2014; Laderach et al., 2013).. In 
contrast, recent studies indicated that targeting Gal-3 in the stroma or parenchyma of 
melanoma cells impaired angiogenesis through modulation of VEGF- and TGF--dependent 
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 pathways (Machado et al., 2014). These findings are consistent with the ability of Gal-3 to 
potentiate VEGF- and FGF2-mediated angiogenesis through mechanisms involving binding to 
complex N-glycans on integrin v3 and cell surface retention of VEGFR2 (Markowska et al., 
2010; 2012). Notably, Nangia-Makker and colleagues showed that cleavage of the N-
terminus of Gal-3 by matrix metaloproteinases (MMPs) represents a critical step for 
stimulating breast cancer angiogenesis (Nangia-Makker et al., 2010). Furthermore, 
LGALS3BP, a protein known to specifically bind Gal-3, functions as a pro-angiogenic mediator 
through a dual mechanism involving induction of tumor VEGF or stimulation of EC function 
by Gal-3 (Piccolo et al., 2013).  
Regarding other members of the galectin family, recent studies documented an 
indirect role of Gal-2, Gal-4 and Gal-8 in angiogenesis programs by inducing the secretion of 
EC-derived cytokines and chemokines (G-CSF, IL-6, MCP-1 and GROα), which in turn can 
stimulate EC signaling (Chen et al., 2014). Altogether, these studies indicate non-redundant 
roles of individual members of the galectin family in the control of EC biology, which may 
support angiogenesis through different mechanisms involving: a) engagement of distinct EC 
receptors; b) activation of divergent signaling pathways; and/or c) independence or 
interdependence of canonical angiogenic ligands. 
 
Mechanisms of resistance to anti-angiogenic therapies: the glycan connection 
The initial experiments of Judah Folkman were the inspiration for targeting angiogenesis as a 
mean of eradicating tumors (Folkman et al., 1971). Later, the identification of VEGF as a 
central mediator of angiogenesis and the elucidation of its specific receptors (VEGFRs) have 
enabled the design of selective inhibitors that block the vascularization process (Ferrara et 
al., 2004). The master pro-angiogenic factor VEGF acts through activation (dimerization, 
phosphorylation and signaling) of VEGFRs including VEGFR1, VEGFR2 and VEGFR3 on ECs 
(Ferrara et al., 2004).  
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 Most anti-angiogenic therapies are designed to disrupt VEGF-VEGFR interactions 
through: a) sequestering soluble VEGF using an anti-VEGF blocking Ab (bevacizumab), b) 
inhibiting VEGFR tyrosine kinase activity using receptor tyrosine kinase (RTK) inhibitors such 
as sunitinib, sorafenib, pazopanib, vandetanib, cabozantinib, tivozatinib, linifanib and 
axitinib) that target VEGFRs through direct competition with ATP to the intracellular tyrosine 
kinase binding domain (Loges et al., 2009).  
Although VEGF-targeted therapies have increased progression-free survival and in 
some cases overall survival in patients with colorectal cancer, NSCLC, metastatic breast 
cancer, renal cell carcinoma and advanced hepatocarcinoma, the clinical benefits conferred 
by these therapies are, at most temporary, and tumors eventually reinitiate growth, 
suggesting that alternative angiogenic pathways may be invoked in the absence of VEGF 
signaling to preserve tumor vascularization (Bergers and Hanahan, 2008; Ebos et al., 2009). 
In fact, tumors develop a number of strategies to circumvent antiangiogenic treatment. 
Whereas some tumors are intrinsically refractory to antiangiogenic therapies (intrinsic 
resistance), in most cases tumors develop adaptive resistance mechanisms to circumvent 
specific angiogenic blockade (evasive resistance) (Bergers and Hanahan, 2008). Pathways of 
evasive resistance involve the expression of alternative angiogenic factors including FGF2, 
placental growth factor (PIGF), PDGF-, IL-6, IL-8, angiopoietins (Ang2) or hepatocyte 
growth factor (HGF), which stimulate angiogenic compensatory programs and limit the 
efficacy of anti-VEGF treatment (Berger and Hanahan, 2008, Shojaei et al., 2010). In 
addition anti-angiogenic treatments induce an initial ‘vessel pruning’ effect, which aggravates 
tumor hypoxia and favors revascularization and tumor metastasis (Paez-Ribes et al, 2009; 
Ebos et al., 2009). Indeed in Darwinian terms hypoxia acts as a pressure mechanism that 
selects tumor cell variants with increased aggressiveness and lower sensitivity to anti-
angiogenic therapy. Finally, an additional mechanism involves mobilization of angio-
competent myeloid cells, which in response to hypoxic conditions or to anti-angiogenic 
treatment, preserves vascularization programs. This includes the recruitment of TIE2+ 
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 monocytes (De Palma et al., 2005), Bv8-expressing CD11b+ Gr1+ myeloid-derived suppressor 
cells (MDSCs) (Shojaei et al., 2007) and VEGFR1+ macrophages (Hattori et al., 2002) which, 
upon reaching the tumor microenviornments secrete potent proangiogenic mediators such as 
VEGF, FGF2 and TGF- (Murdoch et al., 2008). Interestingly, IL-17 (released by Th17 cells) 
induces the secretion of granulocyte colony-stimulating factor (G-CSF) by tumor-associated 
fibroblasts, which in turn promotes the mobilization of Bv8-expressing CD11b+Gr1+ MDSCs 
and stimulates tumor angiogenesis (Chung et al., 2013).  
 In recent studies, we identified a glycosylation-based mechanism mediated by Gal-1-
N-glycan interactions that links tumor hypoxia to VEGFR2 signaling and preserves 
angiogenesis in the setting of VEGF blockade (Croci et al., 2014). We found that Gal-1 binds 
directly to non-sialylated N-glycans on VEGFR2 and promotes segregation and retention of 
this glycosylated receptor on the surface of ECs. This glycosylation-based mechanism leads 
to VEGFR2, Erk1/2 and Akt phosphorylation and mimics VEGF signaling. Although Gal-1 
preferentially bound VEGFR2 (Croci et al., 2014), further studies should examine in detail the 
glycosylation status of other EC receptors including c-Met, FGFR and PDGFRs under different 
experimental conditions. 
 Remarkably, tumor refractory to VEGF blocakde (Lewis lung carcinoma; LLC1 and 
R1.1 T cell lymphoma) produced high amounts of Gal-1 in response to hypoxia or anti-VEGF 
treatment and their associated vasculature displayed glycosylation patterns that facilitated 
Gal-1-EC interactions, including increased β1-6GlcNAc branching, diminished display of 2-6-
linked sialic acid and greater exposure of poly-LacNAc-extended glycans. In contrast, vessels 
associated to anti-VEGF sensitive tumors (B16 melanoma and CT26 colon carcinoma) 
displayed high amounts of α2,6-linked sialic acid in response to VEGF blockade, which 
prevented Gal-1 binding and angiogenesis. Accordingly, loss of 2-6-sialylation in tumor-
associated vessels conferred reduced sensitivity to anti-VEGF treatment and favored 
compensatory angiogenesis mediated by Gal-1-receptor interactions. In contrast, lack of β1-
6 GlcNAc-branched N-glycans in ECs or silencing of tumor-derived Gal-1 converted refractory 
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 into anti-VEGF-sensitive tumors (Croci et al., 2014). Although host cells including ECs and 
stromal cells also express substantial amounts of Gal-1 (Thijssen et al., 2013), no 
considerable differences in microvessel density were observed when tumor cells from 
Kaposi’s sarcoma or LLC1 were implanted into Gal-1-deficient (Lgals1-/-) or wild-type mice 
(Croci et al., 2012; 2014). These findings highlight the relevance of EC surface glycosylation 
and tumor-derived Gal-1 as potential therapeutic targets to surmount anti-VEGF 
compensatory programs. Interestingly, recent studies disclosed a higher frequency of anti-
Gal-1 antibodies in melanoma patients treated with a combination of anti-VEGF 
(bevacizumab) and anti-CTLA-4 (ipilumimab) antibodies (Hodi et al., 2014). Whether these 
antibodies are the result of increased amounts of circulating Gal-1 in treated patients 
remains to be explored.  
 Targeting Gal1-N-glycans interactions, using an anti-Gal1 monoclonal antibody, 
eliminated resistance to anti-VEGF treatment, suppressed the formation of aberrant tumor 
vascular networks and enhanced anti-tumor immune responses in several tumor models 
(Croci et al., 2012; 2014). Interestingly, antibody-mediated Gal-1 blockade promoted 
transient normalization of tumor-associated vasculature early after treatment, as shown by 
reduced vessel diameter, increased pericyte coverage and maturation and attenuation of 
tumor hypoxia. These effects, which favored influx of anti-tumor immune cells to the tumor 
parenchyma, were also verified in Mgat5-/- mice, thus emphasizing the critical role of 
complex N-glycans in the control of tumor vascularization and immunity (Croci et al., 2014). 
In addition, these findings underscore the dual effects of blocking Gal-1-N-glycan 
interactions, which influence tumor growth by attenuating aberrant angiogenesis and 
potentiating anti-tumor responses. Supporting these findings, treatment of tumors with both 
bevacizumab and anginex, an anti-angiogenic peptide known to bind Gal-1, normalized 
tumor vessels, increased oxygenation and improved responses to radiation therapy (Dings et 
al., 2007). Moreover, administration of OTX008, a synthetic compound that targets Gal-1, 
potentiated the activity of the tyrosine kinase inhibitor sunitinib in nude mice inoculated with 
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 tumor xenografts (Zucchetti et al., 2013). These results support the use of combination 
therapies containing Gal-1-blocking agents to maximize the efficacy of anti-cancer 
treatments.  
 
Conclusions and future challenges 
In the present review we summarize the emerging roles of glycans and glycan-binding 
proteins (particularly galectins) in angiogenesis-related processes with particular emphasis in 
tumor vascularization and resistance to anti-angiogenic therapies. First, we discuss the 
relevance of glycosylation in regulating angiogenesis by controlling Notch signaling, EC 
migration and branching, EC survival and vascular permeability. Next, we highlight the role 
of lectin-glycan recognition systems, particularly those involving galectins, in regulating 
receptor segregation, endocytosis and signaling. Finally, we discuss the implications of a 
glycosylation-based mechanism mediated by direct Gal-1-receptor interactions that links 
tumor hypoxia to VEGFR2 signaling and preserves angiogenesis in the setting of VEGF 
blockade.  
 Challenges for the future will embrace: a) a systematic study of the EC glycome in 
tumor-associated vessels compared to those irrigating inflamed and healthy tissues in pre-
clinical and clinical settings; b) a comprehensive analysis of different lectin-glycan systems 
(including those involving C-type lectins, siglecs and other galectin family members) in 
vascular signaling programs; and c) the integration of the Gal-1-N-glycan axis to other 
angiogenic rescue programs with the ultimate goal of maximizing the efficacy of anti-
angiogenic treatments.  
Future anti-cancer therapies will require the rational combination of tumor-targeted 
therapies (i.e. those aimed at disrupting biochemical and metabolic pathways in tumors; e.g. 
EGFR inhibitors); immunotherapeutic approaches (i.e. those targeting negative regulatory 
checkpoints, such as CTLA-4 or PD-1/PD-L1) and anti-angiogenic agents (i.e. those 
promoting vessel pruning or normalization). Given its dual immunostimulatory and anti-
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 angiogenic effects, targeting Gal-1 (and probably other galectins in the tumor 
microenvironment) might serve to potentiate current anti-cancer strategies and maximize 
their therapeutic efficacy. Future pre-clinical studies should be aimed at exploring these 
combination strategies, studying their pharmacokinetics and distribution and analyzing their 
toxicity and potential side effects. 
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 Legend to figures 
Figure 1. Mechanisms of resistance to anti-angiogenic therapies. Tumors develop 
several strategies to evade anti-angiogenic treatment. While some tumors are intrinsically 
refractory and do not response to anti-angiogenic therapies even at early stages of 
treatment, others acquire evasive resistance mechanisms to circumvent angiogenic blockade 
(evasive resistance). Mechanisms of evasive resistance involve the secretion of alternative 
pro-angiogenic mediators including fibroblast growth factor-2 (FGF2), platelet-derived 
growth factor (PDGF)-, IL-17, IL-6, IL-8, angiopoietin-2 (Ang-2) and hepatocyte growth 
factor (HGF), which may fuel revascularization programs and limit the efficacy of anti-VEGF 
treatment. Anti-angiogenic therapies may also lead to severe hypoxia as a result of vessel 
pruning which could act as a major driving force for the generation of angiogenic rescue 
programs and tumor metastasis. Moreover, mobilization of angio-competent myeloid 
regulatory cells (TIE2+ monocytes, Bv8-expressing CD11b+ Gr1+ myeloid-derived suppressor 
cells (MDSCs) and VEGFR1+ macrophages) may also preserve angiogenesis in anti-VEGF 
treated tumors through secretion of key proangiogenic factors. Emerging evidence indicates 
that Gal-1 interactions with complex N-glycans on ECs contribute to preserve angiogenesis in 
anti-VEGF refractory tumors. 
 
Figure 2. Glycosylation-dependent Gal1-VEGFR2 interactions maintain 
angiogenesis in anti-VEGF refractory tumors. Hypoxic microenvironments generated in 
response to VEGF blockade instruct anti-VEGF refractory tumors (left pannel) to secrete 
higher amounts of Gal-1 and their associated vasculature displays Gal-1-specific glycans 
(increased β1-6GlcNAc branching and poly-LacNAc-extended glycans and diminished display 
of 2,6-linked sialic acid). This inducible EC glycophenotype facilitates Gal1 binding, 
compensatory angiogenesis and tumor growth. In contrast, vessels associated with anti-
VEGF sensitive tumors (right panel) display higher amounts of α2,6-linked sialic acid, which 
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 prevent Gal-1-VEGFR2 interactions. Gal-1 is depicted in blue in its prototypic dimeric form. 
For mechanistic details please see the text. 
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